舒泰神:预计2025年净亏损6981.35万元-8532.76万元

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, indicating a challenging financial outlook for the upcoming year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to range from -90.56 million to -74.09 million yuan for 2025 [1] - Projected operating revenue for the same period is estimated to be between 198.31 million and 242.38 million yuan [1] Business Operations - During the reporting period, the company's production and operational activities were normal, with a slight increase in sales revenue and volume for the product Su Tai [1] - The revenue from the product Shutaqing has decreased due to external environmental factors and industry policies, prompting the company to explore multiple channels for market expansion [1] Product Development - The company is focusing on marketing efforts for its polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Sitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yiqing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shu Changqing)" [1] Non-recurring Gains and Losses - The company expects non-recurring gains and losses for 2025 to be approximately 4.75 million yuan, with specific figures to be disclosed in the annual report [1]

Staidson BioPharm-舒泰神:预计2025年净亏损6981.35万元-8532.76万元 - Reportify